Biosimilar Medicines: Core Principles and Communication

This module was developed to support the clinical practice of physicians prescribing biosimilar medicines to cancer patients. The content is designed to promote a clear understanding of biosimilar medicines with a focus on improving patient education through good communication.

This project was made possible through a collaboration between European Cancer Patient Coalition (ECPC), King’s College London and ecancer.

Published July 2019.

Learning objectives

By the end of the module you will:

Be able to define a biosimilar product vs generic product.

Understand how the ‘nocebo effect’ occurs and how to prevent it.

Understand the ethics around interchangeability and switching biosimilar medicines.

Acquire key patient communication skills to help you answer difficult questions on biosimilars.

IT Requirements

This module requires the learner to have a good, stable internet connection and can run on Internet Explorer 7 and above, Mozilla Firefox, Google Chrome and Opera on either Windows or MacOS. Flash Add-on is also required to run this module.

If you are viewing this module on an iPad (through a browser), please download the free Articulate Mobile Player beforehand. Other tablet devices may not be compatible - please check for Flash compatibility.

If you are experiencing technical difficulties, please contact education@ecancer.org and we will get back to you as soon as possible.

Disclosure policy

ecancer and everyone involved in the development of this module has no actual or potential conflict of interest whatsoever which impinges on the making, peer reviewing and dissemination of this e-learning module which was made possible through an unrestricted educational grant from Pfizer.

Pfizer has had no input in the creation of the e-learning materials including the process of selecting speakers.

For more information please contact education@ecancer.org.